cc-115
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 25, 2011 (NCT01353625)
Timeline
Indications
Mechanism of action
- DNA-dependent protein kinaseINHIBITOR
PRKDC inhibitor
ATP-competitive mTORC1/mTORC2 inhibitor
- Serine/threonine-protein kinase mTORINHIBITOR
MTOR inhibitor
ATP-competitive mTORC1/mTORC2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCN1C(=O)CNc2ncc(-c3ccc(-c4nc[nH]n4)nc3C)nc21- Mol. weight
- 336.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3586573 ↗
- ChEMBLCHEMBL3545426 ↗
Also known as
- 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1h)-one
- cc-115
- cc-115
- cc-115
- cc-115
- cc-115
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02977780 | Phase 2 | Feb 9, 2017 | Accelerate Brain Cancer Cure, Celgene, Eli Lilly, Harvard University, Puma Biotechnology, Inc. |
| NCT02833883 | Phase 1 | Jul 1, 2016 | Celgene, Cornell University |
| NCT01353625 | Phase 1 | Apr 25, 2011 | Celgene |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 3 | 1 | 2 | 2011 |
| Accelerate Brain Cancer Cure | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Eli Lilly | For profit | 1 | 0 | 1 | 2017 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Puma Biotechnology, Inc. | For profit | 1 | 0 | 1 | 2017 |
6 organizations
Page 1 / 1